Towa Pharmaceutical Co., Ltd.

Tokyo Stock Exchange 4553.T

Towa Pharmaceutical Co., Ltd. Return on Capital Employed (ROCE) for the year ending March 31, 2024: 5.03%

Towa Pharmaceutical Co., Ltd. Return on Capital Employed (ROCE) is 5.03% for the year ending March 31, 2024, a 167.31% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

Towa Pharmaceutical Co., Ltd. Return on Capital Employed (ROCE) for the year ending March 31, 2023 was 1.88%, a -78.17% change year over year.
Towa Pharmaceutical Co., Ltd. Return on Capital Employed (ROCE) for the year ending March 31, 2022 was 8.63%, a -15.95% change year over year.
Towa Pharmaceutical Co., Ltd. Return on Capital Employed (ROCE) for the year ending March 31, 2021 was 10.26%, a 0.72% change year over year.
Towa Pharmaceutical Co., Ltd. Return on Capital Employed (ROCE) for the year ending March 31, 2020 was 10.19%, a -5.10% change year over year.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

Tokyo Stock Exchange: 4553.T

Towa Pharmaceutical Co., Ltd.

CEO	Mr. Itsuro Yoshida
IPO Date	April 5, 2004
Location	Japan
Headquarters	2-11, Shinbashi-cho
Employees	4,588
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Cosmetics Personal Care

Description

Towa Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells ethical drugs, active pharmaceutical ingredients, and intermediates in Japan. The company provides its products in the therapeutic areas of diabetes, digestive system, nervous system, and allergic diseases, as well as vitamins, antibiotics, and oncology products. It had a portfolio of approximately 700 drug products. Towa Pharmaceutical Co., Ltd. was founded in 1951 and is headquartered in Osaka, Japan.

Key trends

Past 5 years